Difference between revisions of "Team:Waterloo"
| Line 1: | Line 1: | ||
| − | |||
<html> | <html> | ||
<div class="jumbotron"> | <div class="jumbotron"> | ||
| − | <div class=" | + | <div class="container"> |
| − | <div class="text-center"> | + | <div class="row vertical-align"> |
| + | <div class="col-sm-6 text-center"> | ||
<h2> | <h2> | ||
| − | + | <font color="#fbb67a">Swappable sgRNA Targets</font> | <font color="#79bcc7">Engineered PAM Flexibility</font> | <font color="#92cc78">Antiviral Protection for Plants</font></h2> | |
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
<div class="col-sm-6"> | <div class="col-sm-6"> | ||
| − | <img src="/wiki/images/1/1c/Waterloo_crispier_logo.png" alt="Waterloo iGEM CRISPieR Logo | + | <img src="/wiki/images/1/1c/Waterloo_crispier_logo.png" alt="Waterloo iGEM CRISPieR Logo" class="img-responsive"/> |
</div> | </div> | ||
| + | </div> | ||
</div> | </div> | ||
</div> | </div> | ||
| Line 18: | Line 16: | ||
<div id ="contentContainer"> | <div id ="contentContainer"> | ||
</html> | </html> | ||
| + | {{Waterloo}} | ||
<html> | <html> | ||
<h2>Re-engineering CRISPR-Cas9 with functional applications in eukaryotic systems</h2> | <h2>Re-engineering CRISPR-Cas9 with functional applications in eukaryotic systems</h2> | ||
Revision as of 01:52, 15 September 2015
Swappable sgRNA Targets | Engineered PAM Flexibility | Antiviral Protection for Plants
Re-engineering CRISPR-Cas9 with functional applications in eukaryotic systems
CRISPR-Cas9 is an exciting tool for synthetic biologists because it can target and edit genomes with unprecedented specificity. Our team is attempting to re-engineer CRISPR to make it more flexible and easier to use.
We’re making it easy to test different sgRNA designs: restriction sites added to the sgRNA backbone allow 20 nucleotide target sequences to be swapped without excessive cloning.
Additionally, we’re applying recent research on viable mutations within Cas9’s PAM-interacting domain to design (d)Cas9 variants that bind to novel PAM sites, moving towards the goal of a suite of variants that can bind any desired sequence. We believe our re-engineered CRISPR-Cas9 will give biologists increased ability to optimize targeting in many applications.
The application we chose to explore is a proof-of-concept antiviral system defending the model plant Arabidopsis thaliana against Cauliflower Mosaic Virus, which would benefit from testing a large number of possible sgRNAs in the viral genome.